3 news items
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
ONVO
21 May 24
in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2023, as such risk factors are updated in its most
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
ONVO
14 May 24
factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
ONVO
8 May 24
, that was declared effective by the Securities and Exchange Commission (the "SEC") on May 8, 2024. The offering is being made only by means of a prospectus
- Prev
- 1
- Next